Compare Neurocrine Biosciences Inc (NBIX) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Neurocrine Biosciences Inc trades at $142.19 (market cap $14.36B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.36 (market cap $323.80B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 22.5× Neurocrine Biosciences Inc's market cap, and Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Vanguard Tax Managed Fund FTSE Developed Markets ETF for 131 Days on average.
| NBIX | VEA | |
|---|---|---|
Market Cap | $14.36B | $323.80B |
Volume | 1,237,180 | 17,001,112 |
Sector | Health | — |
52-Week High | $185.50 | $73.79 |
52-Week Low | $123.10 | $58.90 |
Typical Hold Time | 23 Days | 131 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
VEA trades at $70.21, down 0.07% with bearish technical signals dominating. The ETF shows mixed institutional activity with several firms increasing positions while others reduced exposure. Recent news highlights VEA's competitive advantages including its 0.03% expense ratio and focus on developed markets excluding the U.S. The current technical setup shows oversold conditions with RSI at 28.40 suggesting potential near-term bounce opportunity.
VEA presents a cost-efficient developed markets exposure with strong dividend yield appeal, though technical indicators signal caution. Key risks include global market volatility and currency fluctuations. The ETF's institutional ownership trends and competitive expense ratio support its long-term positioning for investors seeking international diversification beyond U.S. markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
